{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.6.4.2 Clinical Measures of Severity', '104', '9.6.4.2.1', 'Motility Component of the Clinical Measures of Severity', '104', '9.6.4.3 Clinical Activity Score (CAS)', '104', '9.6.4.3.1', 'Stratification of Proptosis and CAS Response into Four Responses', 'Categories', '104', '9.6.4.4 Quality of Life Analysis', '105', '9.6.4.5 Blood and Serum Biomarkers', '105', '9.6.4.6', 'Safety Analyses', '105', '9.6.4.7 Interim Analyses', '105', '9.6.5', 'Sample Size and Power Considerations', '105', '9.7 Changes in the Conduct of the Study', '106', '10', 'SOURCE DOCUMENTATION AND INVESTIGATOR FILES', '106', '11', 'CASE REPORT FORMS', '107', '12', 'STUDY MONITORING', '107', '13', 'DATA MANAGEMENT', '108', '14', 'RETENTION OF RECORDS', '109', '15 PUBLICATION', '109', '16 REFERENCES', '109', '17 APPENDICES', '115', '17.1', 'Administrative Appendix', '115', '17.2 Proptosis (Exophthalmometry) Method', '116', \"17.3 Graves' Ophthalmopathy Quality of Life Questionnaire\", '117', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 37 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'LIST OF TABLES', 'Table 6.1', 'Table of Non-Sponsor Study Responsibilities', '44', 'Table 7.1', 'Single-Dose Pharmacokinetic Parameters (CHO Material)', '54', 'Table 7.2', 'Summary of TEAEs Reported in at Least 5% of Subjects in Teprotumumab', 'Treatment Group and % is Greater Than Placebo', '56', 'Table 7.3', 'Summary of SAEs Reported in Either Treatment Group by Preferred Term', '57', 'Table 9.1', 'Restricted Medications and Therapies', '77', 'Table 9.2 Clinical Activity Score (CAS) Assessment', '79', 'Table 9.3', 'Clinical Measures of Severity', '80', 'Table 9.4', 'Schedule of Clinical Laboratory Safety Tests, Including Thyroid Panel and', 'Hyperglycemia Monitoring', '90', 'LIST OF FIGURES', 'Figure 7.1 Thyroid Eye Disease Photographs', '47', 'Figure 9.1 Schematic of Study Design', '65', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 38 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '4', 'LIST OF ABBREVIATIONS', 'Abbreviation', 'Definition', 'A subscale', 'Appearance subscale of GO-QoL', 'ADA', 'Anti-drug antibody', 'AE', 'Adverse event', 'AESI', 'Adverse event of special interest', 'ALT', 'Alanine aminotransferase', 'ANCOVA', 'Analysis of covariance', 'APD', 'Afferent pupillary defect', 'AST', 'Aspartate aminotransferase', 'AUC', 'Area under the concentration-time curve', 'CAS', 'Clinical activity score', 'CFR', 'Code of Federal Regulations', 'CHO', 'Chinese hamster ovary', 'CI', 'Confidence interval', 'CL', 'Clearance', 'Cmax', 'Maximum observed concentration', 'CMH', 'Cochran-Mantel-Haenszel', 'CPI', 'Coordinating principal investigator', 'CRO', 'Contract research organization', 'CS', 'Clinically significant', 'Ctrough', 'Trough concentration', 'CV', 'Coefficient of variance', 'DSMB', 'Data safety monitoring board', 'EAA', 'European Economic Area', 'ECG', 'Electrocardiogram', 'eCRF', 'Electronic case report form', 'EU', 'European Union', 'EUGOGO', \"European Group on Graves' Ophthalmopathy\", 'FDA', 'Food and Drug Administration', 'FT3', 'Free triiodothyronine', 'FT4', 'Free thyroxine', 'GCP', 'Good Clinical Practice', 'GD-IgG', \"Graves' disease immunoglobulin G\", 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 39 of 117']\n\n###\n\n", "completion": "END"}